Recombinant African swine fever virus antigen cocktail vaccine and application thereof

Abstract

The invention relates to a recombinant African swine fever virus antigen'cocktail 'vaccine and application thereof, and belongs to the field of biotechnological pharmacy, the'cocktail' vaccine is prepared by compatibility of three components including an N-segment amino acid sequence of recombinant protein p30-modified p54, p72 epitope-pE248R, an N-segment amino acid sequence of CD2v and a C-segment amino acid sequence of pEP153R with an adjuvant. The invention provides expression and purification methods of the three recombinant proteins, and proportions and adjuvants of the recombinant proteins for preparing the cocktail vaccine. The cocktail vaccine for immunizing pigs can stimulate the body to generate neutralizing antibodies and cellular immunity, and is an African swine fever subunit vaccine with a very good application prospect.

Description

technical field [0001] The invention belongs to the field of biotechnology and pharmaceuticals, in particular to a recombinant African swine fever virus antigen "cocktail" vaccine and its application. Background technique [0002] African swine fever (ASF) is an acute and severe infectious disease of pigs caused by African swine fever virus (ASFV), with a mortality rate of up to 100%. Currently, there is no commercial vaccine available. The World Organization for Animal Health (OIE) lists it as an animal disease that must be notified, and my country lists it as a first-class animal infectious disease that must be prevented and controlled. Since the discovery of ASFV, research on vaccines has never stopped. However, due to the large virus genome, numerous encoded proteins and complex structures, and unclear mechanisms of immunity and infection, there is no safe and effective vaccine available so far. Studies on ASF vaccines have shown that: (1) ASF inactivated vaccine cannot...

AI Technical Summary

Problems solved by technology

Since the discovery of ASFV, the research on vaccines has never stopped. However, due to the large genome of the virus, the numerous encoded proteins and complex structures, and the unclear mechanism of immunity and infection, there is no safe and effective vaccine available so far.

Studies on ASF vaccines have shown that: (1) ASF inactivated vaccine cannot provide immune protection; (2) ASF live attenuated vaccine can protect homologous or heterologous strain infection, but it will cause adverse reactions and there is a risk of virulence reversion

(3) ASF subunit vaccines can induce neutralizing antibodies, but the immune protection effect is not satisfactory. It is necessary to design a new multi-component subunit vaccine with a variety of protective antigens to improve the immune protection level of subunit vaccines

In short, in view of the complex immune protection mechanism of ASFV, it is particularly important to design a subunit vaccine composed of multi-component antigens to broaden the antigen spectrum and neutralizing antibody level, which is one of the important means to solve the unsatisfactory immune protection effect of the current subunit vaccine

Images